{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:56:59Z","timestamp":1783727819889,"version":"3.55.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an important healthcare-associated pathogen. We evaluated the impact of CRKP strain type and treatment on outcomes of patients with CRKP bacteriuria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Physician-diagnosed CRKP urinary tract infection (UTI)\u2014defined as those patients who received directed treatment for CRKP bacteriuria\u2014was studied in the multicentre, prospective Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle) cohort. Strain typing by repetitive extragenic palindromic PCR (rep-PCR) was performed. Outcomes were classified as failure, indeterminate or success. Univariate and multivariate ordinal analyses to evaluate the associations between outcome, treatment and strain type were followed by binomial analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One-hundred-and-fifty-seven patients with physician-diagnosed CRKP UTI were included. After adjustment for CDC\/National Healthcare Safety Network (NHSN)-defined UTI, critical illness and receipt of more than one active antibiotic, patients treated with aminoglycosides were less likely to fail therapy [adjusted OR (aOR) for failure 0.34, 95% CI 0.15\u20130.73, P\u200a=\u200a0.0049]. In contrast, patients treated with tigecycline were more likely to fail therapy (aOR for failure 2.29, 95% CI 1.03\u20135.13, P\u200a=\u200a0.0425). Strain type data were analysed for 55 patients. The predominant clades were ST258A (n\u200a=\u200a18, 33%) and ST258B (n\u200a=\u200a26, 47%). After adjustment for CDC\/NHSN-defined UTI and use of tigecycline and aminoglycosides, infection with strain type ST258A was associated with clinical outcome in ordinal analysis (P\u200a=\u200a0.0343). In multivariate binomial models, strain type ST258A was associated with clinical failure (aOR for failure 5.82, 95% CI 1.47\u201328.50, P\u200a=\u200a0.0113).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this nested cohort study of physician-diagnosed CRKP UTI, both choice of treatment and CRKP strain type appeared to impact on clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dku495","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T02:09:45Z","timestamp":1418177385000},"page":"1203-1211","source":"Crossref","is-referenced-by-count":50,"title":["Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant <i>Klebsiella pneumoniae<\/i>"],"prefix":"10.1093","volume":"70","author":[{"given":"David","family":"van Duin","sequence":"first","affiliation":[{"name":"1 \u00a0Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Cober","sequence":"additional","affiliation":[{"name":"2 \u00a0Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S.","family":"Richter","sequence":"additional","affiliation":[{"name":"3 \u00a0Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perez","sequence":"additional","affiliation":[{"name":"4 \u00a0Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA"},{"name":"5 \u00a0Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Kalayjian","sequence":"additional","affiliation":[{"name":"6 \u00a0Department of Medicine, MetroHealth Medical Center, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Salata","sequence":"additional","affiliation":[{"name":"5 \u00a0Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Evans","sequence":"additional","affiliation":[{"name":"7 \u00a0Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"8 \u00a0Division of Infectious Diseases, Duke University, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S.","family":"Kaye","sequence":"additional","affiliation":[{"name":"9 \u00a0Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[{"name":"4 \u00a0Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA"},{"name":"5 \u00a0Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA"},{"name":"10 \u00a0Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, USA"},{"name":"11 \u00a0Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,12,9]]},"reference":[{"key":"2022020120583111300_DKU495C1","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2022020120583111300_DKU495C2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022020120583111300_DKU495C3","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.02636-14","article-title":"Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network","volume":"58","author":"van Duin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3201\/eid1906.121515","article-title":"New Delhi metallo-\u03b2-lactamase-producing Enterobacteriaceae, United States","volume":"19","author":"Rasheed","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2022020120583111300_DKU495C5","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1073\/pnas.1321364111","article-title":"Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae","volume":"111","author":"Deleo","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022020120583111300_DKU495C6","author":"CDC"},{"key":"2022020120583111300_DKU495C7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-8579(98)00060-0","article-title":"Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary","volume":"11","author":"Chow","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"2022020120583111300_DKU495C8","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"2022020120583111300_DKU495C9","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/jac\/dkr240","article-title":"Increasing prevalence and dissemination of NDM-1 metallo-\u03b2-lactamase in India: data from the SMART study (2009)","volume":"66","author":"Lascols","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022020120583111300_DKU495C10","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/cid\/cis036","article-title":"\u201cSilent\u201d dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio","volume":"54","author":"Viau","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020120583111300_DKU495C11","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/JCM.43.8.4178-4182.2005","article-title":"Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates","volume":"43","author":"Diancourt","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2022020120583111300_DKU495C12","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.1111\/j.1469-0691.2012.03886.x","article-title":"Multidrug-resistant (MDR) Klebsiella pneumoniae clinical isolates: a zone of high heterogeneity (HHZ) as a tool for epidemiological studies","volume":"18","author":"Ramirez","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2022020120583111300_DKU495C13","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00125-14","article-title":"Population structure of KPC-producing Klebsiella pneumoniae from midwestern U.S. hospitals","volume":"58","author":"Wright","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C14","doi-asserted-by":"crossref","first-page":"e67847","DOI":"10.1371\/journal.pone.0067847","article-title":"Virulence of Klebsiella pneumoniae isolates harboring bla KPC-2 carbapenemase gene in a Caenorhabditis elegans model","volume":"8","author":"Lavigne","year":"2013","journal-title":"PLoS One"},{"key":"2022020120583111300_DKU495C15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/infdis\/jiu157","article-title":"Carbapenem-resistant Klebsiella pneumoniae exhibit variability in capsular polysaccharide and capsule associated virulence traits","volume":"210","author":"Diago-Navarro","year":"2014","journal-title":"J Infect Dis"},{"key":"2022020120583111300_DKU495C16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/AAC.05079-11","article-title":"Virulence factors and TEM-type \u03b2-lactamases produced by two isolates of an epidemic Klebsiella pneumoniae strain","volume":"56","author":"Robin","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020120583111300_DKU495C19","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","article-title":"Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment","volume":"17","author":"Zarkotou","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2022020120583111300_DKU495C20","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C21","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C22","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1128\/AAC.02445-13","article-title":"Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria","volume":"58","author":"Qureshi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C23","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120583111300_DKU495C24","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.clinthera.2012.05.002","article-title":"Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort","volume":"34","author":"Alexander","year":"2012","journal-title":"Clin Ther"},{"key":"2022020120583111300_DKU495C25","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.107.015735","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects","volume":"35","author":"Hoffmann","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"2022020120583111300_DKU495C26","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12714","article-title":"Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance","author":"Van Duin","year":"2014","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/4\/1203\/42356061\/jac_70_4_1203.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/4\/1203\/42356061\/jac_70_4_1203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:05:09Z","timestamp":1643749509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/4\/1203\/800845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,9]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,12,9]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku495","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,4]]},"published":{"date-parts":[[2014,12,9]]}}}